STC-1010 + cyclophosphamide + sargramostim + mFOLFOX6

This is an investigational combination therapy consisting of four components: - **STC-1010** (specifics unknown; presumed to be a novel or investigational anticancer agent) - **Cyclophosphamide** (an alkylating agent used in cancer chemotherapy, immunosuppressive) - **Sargramostim** (a recombinant human granulocyte-macrophage colony-stimulating factor, stimulates production of white blood cells) - **mFOLFOX6** (a standard chemotherapy regimen that includes oxaliplatin, leucovorin, and fluorouracil[1][2][3][4][5][6][7][8]) mFOLFOX6 is a modified FOLFOX6 regimen with oxaliplatin, leucovorin, and 5-fluorouracil administered as both a bolus and continuous infusion, typically used in colorectal or gastric cancer[1][2][3][4][5]. The overall aim of such combinations is to exploit complementary mechanisms, enhance antitumor efficacy, and manage myelosuppression.